International Clinical Trial: Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (NCT07220577) titled 'Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis' on Oct. 22.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: Novartis Pharmaceuticals

Condition: Atopic Dermatitis

Intervention: Drug: GIA632

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: November 18, 2025

Target Sample Size: 84

To know more, visit https://clinicaltrials.gov/study/NCT07220577

D...